Cardiac manifestations of neonatal lupus include anti-SSA/Ro-SSB/La-mediated conduction system disease and endocardial/myocardial damage resulting in cardiomyopathy. This review will focus on recent data regarding updates on the proposed pathogenesis of disease, morbidity and mortality, and preventive and treatment therapies.
INTRODUCTION
The association between maternal autoantibodies to 52 kD SSA Ro (Ro52), 60 kD SSA Ro (Ro60) and 48 kD SSB/La proteins and the development of fetal cardiac disease is well appreciated. Although advanced conduction system abnormalities have been considered the most characteristic cardiac manifestations of the neonatal lupus syndromes, the spectrum of injury likely extends to the working myocardium and endocardium. For affected families and their physicians, publications in this past year have been highly informative with advances at both the bench and bedside. This review will focus on new data related to pathogenesis, genetics, maternal and fetal risk factors of poor prognosis, and translation of these findings to therapy. Throughout the text, the term 'cardiac neonatal lupus' refers to antibodyassociated heart block as well as more extensive cardiac injury.
PATHOGENESIS OF DISEASE
The incidence of neonatal lupus in an anti-SSA/ Ro-positive mother who is primigravida or has had healthy children approximates 2% [1 && ]. The rarity of disease suggests that the pathogenesis of cardiac injury is not solely related to maternal antibodies. However, it remains possible that antibody reactivity to a specific epitope is responsible for initiation of injury or is more pathogenic than other antibodies. Supportive evidence for specific pathogenicity was provided in a recent study [2 && ], which focused on reactivity to the p200 region (aa200-239) of the Ro52 protein. In a rat model, first-degree atrioventricular block and sinus bradycardia developed in 100 and 81% of pups, respectively, after transfer of maternal antibodies specific for p200. Pups exposed to antibodies targeting N-terminal or C-terminal epitopes of Ro52 did not show ECG abnormalities. This work extends previous studies demonstrating similar ECG abnormalities in rats after passive transfer of immunoglobulin (Ig)G fractions containing anti-SSA/Ro-SSB/La from mothers of children with cardiac neonatal lupus [3] . These findings suggest that anti-p200 contributes to early, and possibly reversible, injury [2 && ]. However, the significance of first-degree block in humans has been challenged in a recent study [4 && ] that concluded, based on serial echocardiograms of 165 anti-SSA/Ro-exposed fetuses, that fetal atrioventricular prolongation does not reliably predict progressive heart block. Despite the limitations raised and the possibility that the rodent model may not fully recapitulate human conditions, the anti-p200 rat model may be extremely useful to further investigate the contribution of fetal genetics to fibrotic replacement of the atrioventricular node.
In considering advanced block as a multistep process, two nonmutually exclusive hypotheses have been proposed to explain the mechanism by which maternal autoantibodies to normally sequestered intracellular antigens initiate injury. One hypothesis is based on molecular mimicry wherein antibodies crossreact with L-type calcium channels (LTCC) and cause dysregulation of calcium homeostasis [5] . Another posits that intracellular anti-SSA/Ro-SSB/La antigens translocate to the surface of cardiomyocytes undergoing apoptosis during physiological remodelling, and thus become accessible to extracelluar antibody [6] . Several recent articles have provided advances for both hypotheses. Based on the prediction that overexpression of LTCC should rescue, whereas knockouts should worsen the ECG abnormalities, Karnabi et al. [7 && ] reported that transgenic pups with overexpression of LTCC, exposed to anti-SSA/Ro-SSB/La antibodies via passive immunization of the mothers, had significantly less sinus bradycardia and atrioventricular block compared with nontransgenic pups. LTCC knockout pups born to immunized mothers had sinus bradycardia, advanced atrioventricular block and decreased fetal parity.
Relevant to the 'apoptotic' theory of cardiac neonatal lupus, in which the formation of pathogenic antibody-apoptotic cell immune complexes promotes proinflammatory and profibrotic responses, Reed et al. [8 && ] demonstrated that b-2 glycoprotein 1 (b2GP1) prevented opsonization of apoptotic cardiomyocytes by maternal anti-Ro60 IgG. Plasmin-mediated cleavage of b2GPI abrogated the inhibition of anti-Ro60 binding, promoting the formation of pathogenic anti-Ro60 IgG-apoptotic cardiomyocyte complexes. Umbilical cord b2GP1 blood levels were significantly lower in anti-Roexposed neonates with cardiac neonatal lupus compared with unaffected siblings. These data suggest intact b2GP1 in the fetal circulation may be a novel cardioprotective factor [8 && ]. The pathogenesis of disease may be fueled by exaggerated apoptosis as observed in the hearts of several fetuses dying with cardiac neonatal lupus [9] . A clue to this observation was the finding that binding of maternal anti-SSA/Ro antibodies to fetal apoptotic cardiocytes impairs their removal by healthy cardiocytes and increases urokinase plasminogen activator (uPA)/uPA receptor (uPAR)-dependent plasmin activation [10] . Briassouli et al. [11 && ] advanced this finding by demonstrating that anti-SSA/Ro binding to apoptotic cardiocytes triggers transforming growth factor beta (TGF-b) activation, an effect secondary to increased uPAR-dependent uPA activity. TGF-b activation might act as an amplifier in the cascade of events that promote myofibroblast transdifferentiation and scar.
Applicable to the potential crosstalk between inflammatory and profibrosing pathways initiated by opsonized apoptotic cardiocytes, Alvarez et al.
[12 && ] identified human fetal cardiac fibroblasts as a source of TGF-b. Supernatants from macrophages incubated with immune complexes comprised Ro60, hY3 ssRNA, and affinity-purified anti-Ro60 antibodies induced fibroblast secretion of TGF-b, which was inhibited by treating the macrophages with an antagonist of toll-like receptor (TLR)-7.
KEY POINTS
Evidence from animal models suggests that reactivity to the p200 region of the Ro52 protein, as well as antibody targeting of L-type calcium channels, may contribute to the development of cardiac neonatal lupus.
In-vitro studies support a protective role of b-2 glycoprotein 1 and a pathologic role of the urokinaseplasminogen activator/receptor system on apoptotic cardiocytes and endothelin-1 secretion by macrophages in the cascade to heart block.
Retrospective studies identify demographic and echocardiographic risk factors such as nonwhite race, earlier time of in-utero detection, slower heart rate and cardiomyopathy as risk factors associated with morbidity and mortality.
Under the same conditions, the induced fibroblast secretion of TGF-b was also decreased by inhibitors of the enodothelin-1 receptors enodothelin-a or enodothelin-b, and by an antienodothelin-1 antibody. In-vivo support for the contribution of enodothelin-1 was based on immunohistochemistry of hearts from two fetuses dying with complete block both revealing the presence of enodothelin-1producing mononuclear cells in the septal region in areas of calcification and fibrosis [12 && ]. The totality of data suggest that enodothelin-1 may be one factor responsible for the profibrosing effects generated by stimulated macrophages [12 && ].
GENETIC CONTRIBUTIONS TO CARDIAC-NEONATAL LUPUS
A focus on variation at the Major Histocompatibility Complex (MHC) was a logical choice for genetic studies, as the extended human leukocyte antigen (HLA)-A1, B8, DR3 haplotype block contains risk alleles for inflammation and certain autoimmune diseases, and is strongly associated with anti-SSA/ Ro-SSB/La antibodies [13] [14] [15] [16] . The same extended haplotype might contribute to a 'double hit', one in the mother and one in her offspring. For example, Strandberg et al. [17] demonstrated in a rodent model that maternal MHC regulated the generation of anti-Ro52 antibodies and that fetal MHC determined susceptibility of the development of a prolonged PR interval.
The role of fetal genetics in development of human disease was investigated in a genome-wide association study [18] of 116 white cardiac neonatal lupus children and 3351 controls, using a 370 000 single nucleotide polymorphism (SNP) platform. The 17 most significant associations were found in the HLA region at 6p21.3. The strongest association, found at rs3099844, is near the class-III MHC region and 94 kb from the TNFa gene, which contains the rs1800629 polymorphism previously associated with cardiac neonatal lupus [19] . Outside of the HLA, no individual locus previously implicated in autoimmune diseases achieved genomewide significance. However, a cluster of associated SNPs at 21q22 were in proximity to the REG-ETS2/ WDR4 transcription factor that serves as a 'brake' to both apoptosis and inflammation, represses the expression of interleukin-8 and plays a role in augmenting the expression of TGF-b receptor type-2. Maternal inheritance may be a limitation of the study because it is difficult to distinguish whether inheritance reflects transmission of genes related to maternal autoimmunity and/or represents enrichment of genes biologically important to disease pathogenesis [18] .
A missense variant at rs7775397 within the C6orf10 gene, which codes for an uncharacterized protein and lies in the class III-class II boundary was also associated with cardiac neonatal lupus in the GWAS [18] . This SNP and the TNFa promoter rs1800629 were evaluated in a multigenerational family study [20 && ] to determine the role of maternal grandparents in the development of the autoimmune phenotype of neonatal lupus mothers. Genotyping was performed in families consisting of 41 neonatal lupus mothers, 38 grandmothers and 29 grandfathers. There was an increased frequency of the two candidate genetic variants in the neonatal lupus mothers compared with haplotype map controls. These frequencies were significantly different between neonatal lupus mothers and grandmothers, but were more similar between the grandfathers and neonatal lupus mothers. Although these data may suggest a differential pattern of transmission between grandmother and grandfather, a formal analysis found no evidence of significant parent of origin effects. The clustering of each genetic variant in neonatal lupus mothers was related to a preferential skewing of inheritance from grandparents, as shown by a Transmission Disequilibrium Test (TDT) of complete trios of mothers and both maternal grandparents. Despite the limited sample size, the TDT analyses were strongly statistically significant because of the magnitude of the effect associated with these HLA-region SNPs. These results imply that mothers accumulate genetic determinants specific to neonatal lupus, which are not present in grandparents. The preferential transmission of risk alleles represents a selection pattern, which demonstrates the 'perfect storm' of events leading to cardiac neonatal lupus. Further study is required to distinguish whether transmission of these genetic risk variants directly contributes to the pathogenesis of neonatal lupus, is restricted to the generation of maternal autoantibodies or is in linkage disequilibrium with the true causal genetic factors [20 && ].
FACTORS CONTRIBUTING TO MORTALITY
Two recent large retrospective studies [21 && ,22 && ] addressed mortality rates and associated risk factors in cardiac neonatal lupus. These studies corroborate and extend findings of previous publications, which included smaller cohorts and a heterogenous mix of autoantibody exposures [23] [24] [25] [26] [27] [28] . Data from the Research Registry for Neonatal Lupus a multiracial/ethnic United States-based registry of anti-SSA/Ro exposed fetuses with neonatal lupus revealed 57 (17.5%) died from complications of cardiac neonatal lupus, 30% of which died in utero. Fetal echocardiographic risk factors associated with increased mortality included hydrops, endocardial fibroelastosis (EFE), earlier diagnosis of cardiac neonatal lupus and lower ventricular rate. The presence of EFE and dilated cardiomyopathy was associated with an increased case fatality rate of 51.9 and 53.3%, respectively, compared with those who only had isolated advanced block (7.8%). Fetuses born to minorities had a higher case fatality rate, possibly because they were at higher risk for developing hydrops and EFE. Pacing was required in 70% of children and four underwent cardiac transplantation [21 && ]. In a multicenter study [22 && ] including 175 patients with advanced heart block from Europe and Brazil (75% were exposed to anti-SSA/ Ro-SSB/La antibodies), 91% resulted in live births and 93% were alive after the neonatal period. Risk factors associated with mortality included gestational age less than 20 weeks at diagnosis, ventricular rate less than 50 beats/min, fetal hydrops and impaired left ventricular function at diagnosis. By 1 year of life, 69% were paced.
APPROACH TO PREVENTION OF DISEASE
Previous literature suggests that use of fluorinated steroids with b-mimetics for fetal heart rates less than 55 improves survival in complete block [29] . However, in the European/Brazilian study [22 && ], there was no significant effect of fluorinated steroids on survival at birth or at 1 month of age, regardless of anti-SSA/Ro exposure. With the exception of gestational age at diagnosis, all other risk factors for mortality were similar between mothers treated and untreated with fluorinated steroids. No improvement was seen in the mortality of fetuses with multiple risk factors despite fluorinated steroids. There was no consensus on treatment guidelines, some referral centers not treating any patient regardless of fetal status and others treating all cases [22 && ]. In the RRNL study [21 && ], fluorinated steroids were associated with an increased mortality in fetuses dying in utero, which was attributed to more severe underlying disease.
Both studies [21 && ,22 && ] also addressed the use of fluorinated steroids for the treatment of seconddegree block. The combined dataset support a trend toward benefit with regression of incomplete block. Specifically, 35% (seven of 20) of fetuses exposed to fluorinated steroids reverted to normal sinus rhythm or first-degree block compared with 6.25% (one of 16) in those not exposed to steroids, P ¼ 0.053 (Table 1) . Long-term data were unavailable in the majority of cases. Data on which children with second-degree atrioventricular block in utero required pacing were only provided in one study preventing a combined analysis. Thus, further studies are needed to determine the durability of steroids in treating incomplete blocks.
Recently, several articles have explored the role of intravenous immunoglobulin (IVIG) in the prevention [30, 31] and treatment [32
&&
,33] of cardiac neonatal lupus. Parallel multicenter, prospective, open-label studies in the United States [30] and Europe [31] addressed whether IVIG reduces the recurrence of cardiac neonatal lupus. IVIG (400 mg/kg) was given every 3 weeks from gestational weeks 12-24 to prevent advanced heart block. Of the 18 mothers completing the US study, there were three cases of advanced block. In the European study, three cases were identified in 15 mothers. Combining data from both studies, there were six (18%) recurrences in 33 women who had previous pregnancies complicated by cardiac neonatal lupus. As each study was designed to conclude inefficacy of IVIG if six of 54 fetuses developed advanced block, the trials were terminated.
Regarding treatment of established cardiac neonatal lupus, a recent study [32 && ] looked at the use of IVIG in combination with steroids for severe cases in which cardiomyopathy/EFE was identified. In this retrospective study, mothers carrying an affected fetus (N ¼ 9) or children recently born with cardiac neonatal lupus (N ¼ 11) were treated with IVIG (approximately 1 g/kg given once or repeated up to three times). Of the 20 cases treated with IVIG, 16 were alive after a median follow-up of 2.9 years and none required cardiac transplantation. The absence of a control arm limited firm conclusions. However, the authors were encouraged by the 80% survival with IVIG treatment compared with three historical case series in which 78% (25 of 32) of cases died or required cardiac transplantation [34] [35] [36] . However, in a recent study [21 && ] the mortality rate of cardiomyopathy/EFE was approximately 50%, and in a second smaller series of five children with isolated EFE, four were alive at 4 years, three of whom had normal heart function [37 && ]. Accordingly, the treatment benefit of IVIG for EFE remains inconclusive.
Based on experimental evidence supporting a role of TLR signaling in the pathogenesis of cardiac neonatal lupus [6] , a recently published case control study [38] explored the hypothesis that hydroxychloroquine (HCQ), an inhibitor of TLR ligation [39] , might reduce the risk of disease. Children born to mothers with Systemic Lupus Erythematosus and anti-SSA/Ro antibodies comprised the cases (50 cardiac neonatal lupus) and controls (151 noncardiac neonatal lupus). Seven (14%) cardiac neonatal lupus children were exposed to HCQ compared with 56 (37%) controls [P ¼ 0.002; odds ratio (OR) 0.28; 95% confidence incidence (CI) 0.12-0.63]. Multivariable analysis yielded an OR associated with HCQ use of 0.46 (P ¼ 0.10; 95% CI 0.18-1.18). Although HCQ was no longer a statistically significant predictor of cardiac neonatal lupus, the estimate of the OR remained in the direction of a protective effect, consistent with the results from the overall unadjusted analysis [38] .
ENVIRONMENTAL INFLUENCE ON THE RISK OF DISEASE
Maternal and fetal factors associated with development of cardiac neonatal lupus were studied in a Swedish population-based cohort [40 && ], which included 190 anti-SSA/Ro-exposed pregnancies. Older maternal age (29.5 vs. 26.6), but not parity, was significantly associated with cardiac neonatal lupus. However, a 2-year age difference is challenging to use as a counseling tool or as an insight into the pathogenesis of disease. In this cohort, cardiac neonatal lupus was present in 58.5% of births with gestational susceptibility weeks 18-24 occurring during January-March, compared with 39% of all births during the remainder of the year. The authors hypothesize that this finding is explained by a decrease in light exposure during the winter months in Sweden that impacts vitamin D levels. The average vitamin D level in each month, calculated based on samples from healthy Swedish women, significantly inversely correlated with the ratio of cardiac neonatal lupus to healthy pregnancies for which gestational week 21 (the median susceptibility week) fell in that particular month [40 && ]. The authors also note that other winter-linked events, such as viral infections, may have accounted for their observations.
CONCLUSION
Evidence from animal models suggests that reactivity to the p200 region of the Ro52 protein, as well as antibody targeting of LTCCs, may contribute to the development of cardiac neonatal lupus. In-vitro studies support a protective role of b2GP1 and a pathologic role of the urokinase-plasminogen activator/receptor system on apoptotic cardiocytes and endothelin-1 secretion by macrophages in the cascade to heart block. Genetic studies highlight the fetal MHC in the development of disease, and a multigenerational study demonstrates that mothers of neonatal lupus children accumulate genetic risk factors preferentially from the neonatal lupus child's grandparents. The ultimate goal, to identify disease-specific genes associated with cardiac neonatal lupus, is of paramount importance in order to understand the molecular pathways that amplify the injurious effects of the maternal autoantibodies. Retrospective studies identify demographic and echocardiographic risk factors such as nonwhite race, earlier time of inutero detection, slower heart rate and cardiomyopathy as risk factors associated with morbidity and mortality. The use of HCQ during pregnancy may provide protection against the development of heart block and future prospective studies evaluating the reduction of recurrence rates are needed.
